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data to estimate the value of a drug for an indication. We
assessed analyses’ compliance with several criteria recommended
by the Panel on Cost-Effectiveness in Health and Medicine.
RESULTS: Of 115 dossiers submitted, 55% included economic
analyses. We found 106 analyses supporting economic claims for
drugs on speciﬁc indications. Of these, 89% adopted a payer per-
spective, 48% were cost minimization analyses, 58% had time
horizons < 2 years. 14% applied discounting; 20% stated all
assumptions clearly; 37% compared relevant alternatives; 21%
reported resource quantities separately, 13% productivity losses,
and 26% incremental results; 42% performed some form of sen-
sitivity analysis; 18% mentioned caveats to conclusions. Analy-
ses of high-cost products were more likely to be cost effectiveness
or cost consequence analyses (OR = 12.5, p = 0.004) and to
compare relevant alternatives (OR = 6.4, p = 0.008). Analyses of
me-too drugs were less likely to state all assumptions clearly 
(OR = 0.23, p = 0.016), compare relevant alternatives (OR =
0.09, p = 0.0001), report sensitivity analyses (OR = 0.19, 
p = 0.006) or incremental results (OR = 0.28, p = 0.03). No 
other signiﬁcant differences found. CONCLUSIONS: Most 
AMCP-Format dossier submissions included economic analyses,
but these had low levels of compliance with accepted recom-
mendations. Analyses of me-too drugs appeared particularly
prone to bias.
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OBJECTIVES: Conventional typical-antipsychotics are less tol-
erated than newer atypical-antipsychotics. Concerns about using
antipsychotic-combinations also exist. However, national studies
of antipsychotic use at United States (US) ambulatory visits are
limited. The study objectives were to determine national esti-
mates and associated factors of antipsychotic (typical, atypical,
and combination) use. METHODS: Retrospective analyses were
conducted of the combined 8-year data (1996–2003) of ofﬁce-
based National Ambulatory Medical Care Survey (NAMCS) and
outpatient National Hospital Ambulatory Medical Care Survey
(NHAMCS). Mental-health disorder visits with ICD-9-CM 
diagnostic-codes (290–319, 331.0x) were classiﬁed into three
mutually exclusive visit-groups: typical, atypical or combined-
antipsychotic. Sample estimates were weighted and projected to
the population with 95% conﬁdence intervals. Multivariable
logistic regression was used to determine signiﬁcant factors asso-
ciated with typical- versus atypical-antipsychotic mention at
visits. RESULTS: About 47.7million visits or 0.83%
(95%CI:0.73–0.93) of all adult visits had a mental-health disor-
der and an antipsychotic mention: atypical (30 million visits),
typical (15.3 million visits), and combination (2.4 million visits).
Major antipsychotics across visit-groups were: typical (haloperi-
dol, thioridazine, ﬂuphenazine); atypical (risperidone, olanzap-
ine, quiteapine); and combination (haloperidol, risperidone,
olanzapine). Compared with typical-, the likelihood of atypical-
antipsychotic visits increased over time. More typical- and 
combination- versus atypical-antipsychotic visits (30% and 
37% vs. 7%) included medications to treat extrapyramidal side
effects (EPS). In multivariable logistic-regression analysis, con-
trolling for gender, schizophrenia-diagnosis, and behavioral-
treatment; age greater than 40 versus 18–40 years (odds-ratio,
OR, 0.65, 95%CI:0.49–0.85) and nonprivate insurance 
reimbursement-sources signiﬁcantly decreased while comorbid
depression (OR, 1.9, 95%CI:1.23–2.85), and bipolar-disorder
(OR, 2.0, 95%CI:1.27–3.24), signiﬁcantly increased the likeli-
hood of atypical- relative to typical-antipsychotic mention at
visits (p < 0.05). CONCLUSIONS: Although combination-
antipsychotic visits were low, 37% of these visits included med-
ications to treat EPS. Atypical-antipsychotic use was more likely
at visits by younger patients, with comorbid diagnoses (depres-
sion, bipolar-disorder), and private insurance reimbursement-
source. This highlights important case-mix factors of
antipsychotic use warranting attention in US ambulatory care to
guide formulary-decisions.
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OBJECTIVES: To reﬁne and evaluate the validity and reliability
of the Hyperpigmentation Treatment Satisfaction Questionnaire
(HPTSQ). The HPTSQ was designed to measure medication
treatment satisfaction for subjects with hyperpigmentation,
either melasma (pregnancy mask) or solar lentigines (age spots).
METHODS: All analyses were conducted on data from a cross-
sectional sample of subjects who reported having hyperpigmen-
tation and completed the HPTSQ online. RESULTS: A total of
635 respondents (573 with solar lentigines and 62 with melasma)
completed the HPTSQ. Factor analysis, Item Response Theory
(IRT) and traditional psychometric analyses were used to select
the 26 items in ﬁve factors/ domains from an initial pool of 38
items. These ﬁve domains had the following properties: 1) Efﬁ-
cacy—7 items, á coefﬁcient 0.96; 2) Side Effects—5 items, á coef-
ﬁcient 0.95; 3) Physical Properties—5 items, á coefﬁcient 0.88;
4) Convenience—5 items, á coefﬁcient 0.87; and 5) Overall Sat-
isfaction—4 items, á coefﬁcient 0.93. Domains 1, 3, 4, and 5
showed strong test-retest reliability (intra-class correlations
0.77–0.87), while Domain 2 had an ICC of 0.44 (0.52 for sub-
jects reporting side effects at both baseline and follow-up). All
domains of the HPTSQ showed strong construct validity when
correlated with related domains on three comparable patient-
reported instruments. Based on level of treatment satisfaction,
all domains of the HPTSQ showed strong known-groups valid-
ity (p < 0.01), except Domain 2 (Side Effects). CONCLUSIONS:
The 26-item HPTSQ is a psychometrically sound and valid
measure of solar lentigines and melasma subjects’ treatment sat-
isfaction with medication. Responsiveness testing of the HPTSQ
should be conducted in a prospective clinical trial.
PR6
VALIDATION OF THE WORK PRODUCTIVITY
QUESTIONNAIRE: RESULTS OF THE MATRIX STUDY
Talati AR1, Pizzi LT1, Dahl N2, Gemmen E3
1Thomas Jefferson University, Philadelphia, PA, USA, 2Watson
Laboratories, Morristown, NJ, USA, 3Quintiles Strategic Research
Services, Falls Church,VA, USA
OBJECTIVE: To determine the validity and sensitivity to change
of the Work Productivity Questionnaire (WPQ) in a large,
national sample of participants in the Multicenter Assessment of
Transdermal Therapy in Overactive Bladder with Oxybutynin
(MATRIX). METHODS: The WPQ is an 8-item subset of the
Work Limitations Questionnaire (WLQ) which measures the
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degree to which health problems interfere with ability to perform
job roles. The WPQ includes physical, mental (concentration),
time (interruptions and adherence to schedule) and output
(ability to handle workload) scales and a WPQ Index is com-
puted to estimate overall productivity loss. In MATRIX, WPQ
scores were compared to the King’s Health Questionnaire
(KHQ), a validated OAB-speciﬁc quality of life (QOL) instru-
ment. We examined the relationship between WPQ scores and
conceptually-related KHQ domains at baseline, and the sensi-
tivity of the WPQ to change in related KHQ measures at 3
months. RESULTS: A total of 1112 employed OAB patients were
enrolled in MATRIX, from 327 US sites. The number of
responses available for each scale at baseline were: time (n = 830,
75%); physical (n = 866, 78%); mental (n = 818, 74%); output
(n = 814, 73%). A WPQ Index was computable for 740 partic-
ipants. Spearman correlations between the KHQ physical limi-
tations domain and the WPQ physical scale was 0.297, and
between the KHQ role limitations and WPQ index score was
0.356. The WPQ appears to be sensitive to change over time,
with WPQ physical scale scores and KHQ physical limitations
score both decreasing at three months and the WPQ Index and
KHQ role limitations also both decreasing at three months.
CONCLUSION: Results suggest that the WPQ is a valid
measure of work productivity in patients with OAB.
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OBJECTIVES: To assess risk indicators for self-reported joint
pain and motion limitation outcomes in hemophilia patients.
METHODS: The Hemophilia Utilization Group Study (HUGS)
examines prospectively the cost and burden of hemophilia,
including arthropathy, quality of life, and economic impact in
patients aged 2 to 65. Parents/patients completed a standardized
interview, including factor use patterns and assessment of joint
pain and motion limitation. Clinical chart reviews were per-
formed to identify the presence of inhibitor antibodies and hemo-
philia severity. Logistic regression was used to evaluate the
association between the factors from the Health Behavioral
Model (predisposing, enabling, need, and health behavior) and
the likelihood of joint pain or motion limitation. RESULTS: Of
the 128 patients with complete outcome data, 70(55%) were
adults, 32(25%) reported joint pain most or all the time,
49(39%) reported severe motion limitation in at least one joint.
Mean age was 23.8 (16.2) years. Risk indicators associated with
joint pain were: 1) predisposing: increasing age (OR = 1.1; 95%
CI = 1.03, 1.1); parent/patient not married/without partner (OR
= 5.7; 1.8, 18.3), and 2) enabling: increasing number of prob-
lems getting care at the hemophilia treatment center (OR = 1.9;
1.03, 3.6). No association was found in need (ever had inhibitor)
and health behaviors (use of factor). Risk indicators associated
with severe motion limitation were: 1) predisposing: increasing
age (OR = 1.1; 95% CI = 1.07, 1.2); parent/patient not
married/without partner (OR = 3.9; 1.3, 12.2); severe hemo-
philia (OR = 21.0; 2.8, 158.9). CONCLUSION: Increasing age,
lack of a support system and more severe hemophilia are useful
characteristics for clinicians to identify patients at greater risk
for joint pain and limitation. Early identiﬁcation of these factors,
which are a major source of disability, may be helpful in avoid-
ing decreased health status and increased medical costs. Address-
ing barriers to receipt of care is of particular import for those
most at risk.
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OBJECTIVES: Abnormal uterine bleeding (AUB) affects up to
30% of women of reproductive age. The purpose of this study
is to quantitatively estimate the impact of AUB on health-related
quality of life (HRQoL). METHODS: A systematic literature
review of studies reporting the impact of AUB or its treatment
on HRQoL published from 1980 to 2005 was conducted from
the PubMed database. We conducted a meta-analysis of eight
studies providing HRQoL scores derived from the 36-item Short
Form Health Survey Questionnaire (SF-36); only baseline SF-36
scores prior to treatment were analyzed. Both random-effect and
ﬁxed-effect models were created and used. The scores were com-
pared with US national norms (weighted average across age
groups 18–24, 25–34, 35–44, and 45–54, obtained from the SF-
36 Health Survey Manual & Interpretation Guide). A subgroup
analysis was conducted to examine whether or not the SF-36
scores differ according to the mean age of each subgroup.
RESULTS: Women with AUB had lower SF-36 scores (worse
health) in all eight subscales; the most signiﬁcantly affected were
Physical Role Functioning and Emotional Role Functioning sub-
scales, which relate to work productivity and other daily activi-
ties. The scores in these two dimensions were approximately 20
points lower than the US population norms (60.3 vs. 84.0 and
62.3 vs. 81.1; highest score = 100). In 6 of the 8 subscales, the
scores for AUB were below the 25th percentile of those for US
national norms (Physical Functioning, Physical Role Function-
ing, Pain, Vitality, Social Functioning, and Emotional Role Func-
tioning). The subgroup analysis suggested that older women had
lower SF-36 scores than younger women; however, the small
number of studies precludes the forming of a deﬁnitive conclu-
sion. CONCLUSIONS: AUB has a signiﬁcant impact on
women’s HRQoL. Treatment for AUB should consider improv-
ing HRQoL status.
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OBJECTIVES: To evaluate the impact of a 90-day retail program
on prescription drug expenditures in a pharmacy beneﬁt man-
agement organization. METHODS: This study was based on
prescription records from pharmacy claims database for a time
period from January 1, 2003 to August 31, 2005. A retrospec-
tive cohort study design with one-year pre period and one-year
post period was employed. Propensity scores were used to match
the study and control clients in terms of patient and client char-
acteristics. Per prescription cost, per member per month (PMPM)
total, plan and member costs and generic utilization rate were
the targeted outcomes. RESULTS: The study group included 25
clients (106,718 lives) enrolled in 90-day retail program, and the
